OMEICOS Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.omeicos.com
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 32
- Registration Number
- NCT05972954
- Locations
- 🇩🇪
Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP, Bonn, Germany
🇩🇪Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40, Halle, Germany
🇩🇪Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a, Munich, Germany
Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT03906799
- Locations
- 🇧🇬
Site 401, Sofia, Bulgaria
🇧🇬Site 404, Stara Zagora, Bulgaria
🇧🇬Site 402, Varna, Bulgaria
Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT03078738
- Locations
- 🇩🇪
CRS-Mönchengladbach, Monchengladbach, Germany